NEW HAVEN, Conn., Oct. 2, 2023 /PRNewswire/ — Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the…